The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of prior ALK-tyrosine kinase inhibitor on pemetrexed-based chemotherapy in patients with advanced ALK positive non-small cell lung cancer.
 
Michitoshi Yabe
No Relationships to Disclose
 
Hirotsugu Kenmotsu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Kyowa Hakko Kirin; Lilly; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Novartis (Inst)
 
Hiroaki Kodama
No Relationships to Disclose
 
Naoya Nishioka
No Relationships to Disclose
 
Eriko Miyawaki
No Relationships to Disclose
 
Taichi Miyawaki
No Relationships to Disclose
 
Nobuaki Mamesaya
No Relationships to Disclose
 
Haruki Kobayashi
No Relationships to Disclose
 
Shota Omori
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; MSD K.K; Novartis; Ono Pharmaceutical
 
Kazushige Wakuda
No Relationships to Disclose
 
Akira Ono
No Relationships to Disclose
 
Tateaki Naito
No Relationships to Disclose
 
Haruyasu Murakami
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); IQvia (Inst); Takeda (Inst)
 
Toshiaki Takahashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD K.K.; Ono Pharmaceutical; Pfizer; Roche
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); MSD K.K. (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)